{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T19:34:33Z","timestamp":1773516873097,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012317","name":"Astellas Pharma Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.euf.2023.04.001","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T15:53:39Z","timestamp":1682610819000},"page":"957-965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials"],"prefix":"10.1016","volume":"9","author":[{"given":"Rano","family":"Matta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Refik","family":"Saskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Neu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Steup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sender","family":"Herschorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2023.04.001_b0005","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.04.001_b0010","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2023.04.001_b0015","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.04.001_b0020","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.04.001_b0025","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.clinthera.2013.08.017","article-title":"Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder","volume":"35","author":"Chancellor","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.euf.2023.04.001_b0030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.euf.2023.04.001_b0035","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2023.04.001_b0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cct.2016.09.005","article-title":"Development of a predictive model for urgency urinary incontinence","volume":"51","author":"Darekar","year":"2016","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.euf.2023.04.001_b0045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","article-title":"A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the \u03b23 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder","volume":"82","author":"Herschorn","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.euf.2023.04.001_b0050","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.04.001_b0055","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5489\/cuaj.3098","article-title":"Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada","volume":"9","author":"Wagg","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.euf.2023.04.001_b0060","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.eururo.2017.01.037","article-title":"Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice","volume":"72","author":"Chapple","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.04.001_b0065","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b2(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.04.001_b0070","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.04.001_b0075","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1756287215589250","article-title":"The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial","volume":"7","author":"Batista","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.euf.2023.04.001_b0080","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2023.04.001_b0085","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2023.04.001_b0090","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.juro.2006.03.088","article-title":"Determining the importance of change in the overactive bladder questionnaire","volume":"176","author":"Coyne","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.04.001_b0095","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.urology.2013.12.027","article-title":"Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?","volume":"83","author":"Herschorn","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.euf.2023.04.001_b0100","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/j.1742-1241.2010.02442.x","article-title":"Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?","volume":"64","author":"Schneider","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.euf.2023.04.001_b0105","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s11255-016-1277-0","article-title":"Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the Consequences of Treatment Refractory Overactive Bladder (CONTROL) study","volume":"48","author":"Chancellor","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.euf.2023.04.001_b0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2490-13-45","article-title":"Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial","volume":"13","author":"Khullar","year":"2013","journal-title":"BMC Urol"},{"key":"10.1016\/j.euf.2023.04.001_b0115","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1471-0528.2004.00137.x","article-title":"Overactive bladder: prevalence, risk factors and relation to stress incontinence in middle-aged women","volume":"111","author":"Teleman","year":"2004","journal-title":"Br J Obstet Gynaecol"},{"issue":"6 Suppl","key":"10.1016\/j.euf.2023.04.001_b0120","first-page":"S2","article-title":"Obesity and urinary incontinence: epidemiology and clinical research update","volume":"182","author":"Subak","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2023.04.001_b0125","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00192-016-3130-5","article-title":"Does BMI, gender or age affect efficacy\/tolerability of solifenacin in the management of overactive bladder?","volume":"28","author":"Cardozo","year":"2017","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.euf.2023.04.001_b0130","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/nau.20787","article-title":"Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release","volume":"29","author":"Chancellor","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.euf.2023.04.001_b0135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejogrb.2015.11.018","article-title":"Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females","volume":"196","author":"Krhut","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.euf.2023.04.001_b0140","doi-asserted-by":"crossref","first-page":"838","DOI":"10.5414\/CP201782","article-title":"Single dose pharmacokinetics and absolute bioavailability of mirabegron, a \u03b23-adrenoceptor agonist for treatment of overactive bladder","volume":"50","author":"Eltink","year":"2012","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923001001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456923001001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:54:27Z","timestamp":1762498467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456923001001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2405456923001001"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2023.04.001","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2023.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}